Liht-naistepuna ürt (Estonian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Liht-naistepuna ürt" in Estonian language version.

refsWebsite

Global rank Estonian rank

11nih.gov

4^th place

14^th place

7doi.org

2^nd place

16^th place

2web.archive.org

1^st place

1google.ee

low place

20^th place

1pharmaxchange.info

low place

1archive.org

6^th place

41^st place

1wkhealth.com

low place

1elsevier.com

610^th place

2,367^th place

1bmj.com

1,226^th place

1,336^th place

archive.org

Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (detsember 2007). "Hyperforin—a key constituent of St. John's wort specifically activates TRPC6 channels". FASEB J. 21 (14): 4101–11. DOI:10.1096/fj.07-8110com. PMID 17666455.{{cite journal}}: CS1 hooldus: mitu nime: autorite loend (link)

bmj.com

Woelk H (september 2000). "Comparison of St John's wort and imipramine for treating depression: randomised controlled trial". BMJ. 321 (7260): 536–9. DOI:10.1136/bmj.321.7260.536. PMC 27467. PMID 10968813.

doi.org

Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K (2006). "Antidepressant use in children and adolescents in Germany". J Child Adolesc Psychopharmacol. 16 (1–2): 197–206. DOI:10.1089/cap.2006.16.197. PMID 16553540.{{cite journal}}: CS1 hooldus: mitu nime: autorite loend (link)
Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (detsember 2007). "Hyperforin—a key constituent of St. John's wort specifically activates TRPC6 channels". FASEB J. 21 (14): 4101–11. DOI:10.1096/fj.07-8110com. PMID 17666455.{{cite journal}}: CS1 hooldus: mitu nime: autorite loend (link)
Nahrstedt A, Butterweck V (september 1997). "Biologically active and other chemical constituents of the herb of Hypericum perforatum L". Pharmacopsychiatry. 30 Suppl 2: 129–34. DOI:10.1055/s-2007-979533. PMID 9342774.
Butterweck V (2003). "Mechanism of action of St John's wort in depression : what is known?". CNS Drugs. 17 (8): 539–62. DOI:10.2165/00023210-200317080-00001. PMID 12775192.
Müller WE (veebruar 2003). "Current St John's wort research from mode of action to clinical efficacy". Pharmacol. Res. 47 (2): 101–9. DOI:10.1016/S1043-6618(02)00266-9. PMID 12543057.
Woelk H (september 2000). "Comparison of St John's wort and imipramine for treating depression: randomised controlled trial". BMJ. 321 (7260): 536–9. DOI:10.1136/bmj.321.7260.536. PMC 27467. PMID 10968813.
Schrader E (märts 2000). "Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression". Int Clin Psychopharmacol. 15 (2): 61–8. DOI:10.1097/00004850-200015020-00001. PMID 10759336.

elsevier.com

linkinghub.elsevier.com

Müller WE (veebruar 2003). "Current St John's wort research from mode of action to clinical efficacy". Pharmacol. Res. 47 (2): 101–9. DOI:10.1016/S1043-6618(02)00266-9. PMID 12543057.

google.ee

books.google.ee

Stefanie Schwartz, "Psychoactive Herbs in Veterinary Behavior Medicine", Blackwell Publishing, lk 18, 2005, Google'i raamatu veebiversioon (vaadatud 20.02.2014) (inglise keeles)

nih.gov

pubmed.ncbi.nlm.nih.gov

Fegert JM, Kölch M, Zito JM, Glaeske G, Janhsen K (2006). "Antidepressant use in children and adolescents in Germany". J Child Adolesc Psychopharmacol. 16 (1–2): 197–206. DOI:10.1089/cap.2006.16.197. PMID 16553540.{{cite journal}}: CS1 hooldus: mitu nime: autorite loend (link)
Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, Müller WE (detsember 2007). "Hyperforin—a key constituent of St. John's wort specifically activates TRPC6 channels". FASEB J. 21 (14): 4101–11. DOI:10.1096/fj.07-8110com. PMID 17666455.{{cite journal}}: CS1 hooldus: mitu nime: autorite loend (link)
Nahrstedt A, Butterweck V (september 1997). "Biologically active and other chemical constituents of the herb of Hypericum perforatum L". Pharmacopsychiatry. 30 Suppl 2: 129–34. DOI:10.1055/s-2007-979533. PMID 9342774.
Butterweck V (2003). "Mechanism of action of St John's wort in depression : what is known?". CNS Drugs. 17 (8): 539–62. DOI:10.2165/00023210-200317080-00001. PMID 12775192.
Müller WE (veebruar 2003). "Current St John's wort research from mode of action to clinical efficacy". Pharmacol. Res. 47 (2): 101–9. DOI:10.1016/S1043-6618(02)00266-9. PMID 12543057.
Woelk H (september 2000). "Comparison of St John's wort and imipramine for treating depression: randomised controlled trial". BMJ. 321 (7260): 536–9. DOI:10.1136/bmj.321.7260.536. PMC 27467. PMID 10968813.
Schrader E (märts 2000). "Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression". Int Clin Psychopharmacol. 15 (2): 61–8. DOI:10.1097/00004850-200015020-00001. PMID 10759336.

ncbi.nlm.nih.gov

Benzie IFF, Wachtel-Galor S, Herbal Medicine: Biomolecular and Clinical Aspects, 2. trükk, CRC Press; 2011, veebiversioon (vaadatud 20.02.2014) (inglise keeles)
Wölfle U, Seelinger G, Schempp CM, Topical application of St. John's wort (Hypericum perforatum). Lühikokkuvõte., Planta Med. 2014 veebruar;80(2–3):109-20. doi: 10.1055/s-0033-1351019., veebiversioon (vaadatud 13.01.2015)(inglise keeles)
Najafizadeh P, Hashemian F, Mansouri P, Farshi S, Surmaghi MS, Chalangari R., The evaluation of the clinical effect of topical St Johns wort (Hypericum perforatum L.) in plaque type psoriasis vulgaris: a pilot study. Lühikokkuvõte., Australas J Dermatol. mai 2012;53(2):131-5. doi: 10.1111/j.1440-0960.2012.00877.x., veebiversioon (vaadatud 13.01.2015)(inglise keeles)
Woelk H (september 2000). "Comparison of St John's wort and imipramine for treating depression: randomised controlled trial". BMJ. 321 (7260): 536–9. DOI:10.1136/bmj.321.7260.536. PMC 27467. PMID 10968813.

pharmaxchange.info

SWEETY MEHTA, [1], 18. detsember 2012, veebiversioon (vaadatud 20.02.2014) (inglise keeles)

web.archive.org

Bianca Mikovitš, Viimane aeg korjata põletiku- ja pohmellivastast naistepuna, veebiversioon (vaadatud 20.02.2014) (inglise keeles)
Jeffrey M. Greeson, Britt Sanford, Daniel A. Monti,"St. John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature.", Psychopharmacology (2001) 153:402–414, DOI 10.1007/s002130000625, veebiversioon (vaadatud 13.08.2013) (inglise keeles)

wkhealth.com

content.wkhealth.com

Butterweck V (2003). "Mechanism of action of St John's wort in depression : what is known?". CNS Drugs. 17 (8): 539–62. DOI:10.2165/00023210-200317080-00001. PMID 12775192.